Aquinox Pharmaceuticals, Inc. (AQXP) Downgraded by Zacks Investment Research to “Sell”
Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Tuesday.
According to Zacks, “Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. “
A number of other analysts also recently commented on the stock. ValuEngine downgraded shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 15th. Canaccord Genuity set a $22.00 target price on shares of Aquinox Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, August 8th. Finally, BidaskClub upgraded shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 4th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $22.25.
Shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) traded up 0.36% on Tuesday, reaching $14.05. 126,049 shares of the company’s stock were exchanged. The stock’s 50-day moving average price is $14.25 and its 200-day moving average price is $14.41. The company’s market capitalization is $329.67 million. Aquinox Pharmaceuticals has a 1-year low of $9.83 and a 1-year high of $19.97.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its quarterly earnings results on Tuesday, August 8th. The company reported ($0.59) EPS for the quarter, hitting analysts’ consensus estimates of ($0.59). Analysts anticipate that Aquinox Pharmaceuticals will post ($2.15) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/10/aquinox-pharmaceuticals-inc-aqxp-downgraded-by-zacks-investment-research-to-sell.html.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Alps Advisors Inc. raised its holdings in shares of Aquinox Pharmaceuticals by 4.7% in the 2nd quarter. Alps Advisors Inc. now owns 21,090 shares of the company’s stock worth $297,000 after purchasing an additional 939 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Aquinox Pharmaceuticals by 3.3% in the 2nd quarter. Northern Trust Corp now owns 83,207 shares of the company’s stock worth $1,171,000 after purchasing an additional 2,691 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Aquinox Pharmaceuticals by 16.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 23,260 shares of the company’s stock worth $327,000 after purchasing an additional 3,299 shares in the last quarter. Archon Partners LLC raised its holdings in shares of Aquinox Pharmaceuticals by 44.0% in the 2nd quarter. Archon Partners LLC now owns 18,000 shares of the company’s stock worth $253,000 after purchasing an additional 5,500 shares in the last quarter. Finally, Investment Centers of America Inc. bought a new stake in shares of Aquinox Pharmaceuticals in the 1st quarter worth approximately $172,000. Institutional investors and hedge funds own 95.15% of the company’s stock.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.